Latest News

Pascal Villemagne appointed new CARBOGEN AMCIS Chief Executive Officer (CEO)

News

Pascal Villemagne appointed new CARBOGEN AMCIS Chief Executive Officer (CEO)

BUBENDORF, Switzerland (March 31, 2022) — Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, announces that Pascal Villemagne has been named Chief Executive Officer, effective first of April

In his new role, Pascal Villemagne will be leading CARBOGEN AMCIS and its nine sites around the world. He will report to Arpit Vyas, Global Managing Director of Dishman Carbogen Amcis Ltd., CARBOGEN AMCIS’ parent company. Villemagne, who has served as Vice President of Sales and Marketing for CARBOGEN AMCIS for the past 11 years, replaces Mark Griffiths who announced his decision to retire.

“We are delighted that Pascal will be transitioning to this new position,” commented Arpit Vyas, Global Managing Director of Dishman Carbogen Amcis Ltd. “As head of sales and marketing, Pascal has contributed greatly to the company’s growth in recent years and he is well positioned to drive our team forward to further success. With tremendous joy, I congratulate Pascal, for all his achievements, including and especially, for finding and accepting this Exciting role of his Life and Career, within Our Family. I have nothing but, confidence, trust and belief in him, to lead the way towards an exciting Future.”

Before joining CARBOGEN AMCIS, Villemagne has had several experiences in the life science industry, amassed while serving in a variety of commercial leadership roles such as Vice President, Contract Manufacturing, at Farmhispania, an API contract manufacturing company based in Spain, Sales and Business Development Manager at Inabata and at Cambrex, as well as Raw Material Purchasing Manager at Sanofi-Aventis.

“CARBOGEN AMCIS is a major player and one of the leaders of the current CDMO in our industry, and this is the result of the engagement, hard work and expertise of its employees,” said Villemagne “That is why I am thrilled and especially proud to take over as CEO of CARBOGEN AMCIS. The company has grown significantly in the past years, and I look forward to continuing our successful journey together. I believe we have the best team to support us in our mission.”

“It is with mixed emotions that, after a 40-year career, including 21 years with CARBOGEN AMCIS, I have decided to retire,” said Griffiths. “It has been a privilege to work with this highly talented and motivated group. I would like to thank all of the employees for their commitment to each other and the company; it has enabled us to overcome many challenges over the years and I feel proud to have been part of that. I wish Pascal all the best in his new role and I have full confidence in his leadership.”

“I would like to recognize Mark’s hard work and achievements at the helm of CARBOGEN AMCIS,” said Vyas. “Mark has been an incredible leader and has contributed to the successful development of our company and I would like to thank him for his trust and commitment. 21 years of association and loyalty with a single Company is, as inspiring as it is, honourable, for the people and for the Company, likewise and respectively. We are nothing but and will, be grateful. We congratulate Mark and with all the best of wishes for all your future endeavours.”

CARBOGEN AMCIS will preserve full operational continuity during the transition and Griffiths will be available to provide guidance on matters related to the company until August 5, 2022.

****

Dishman Carbogen Amcis Ltd (www.imdcal.com) is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and manufacturing services. Dishman Carbogen Amcis group improves its customers’ businesses by providing a range of development and manufacturing solutions at locations in Europe, in China and in India.

CARBOGEN AMCIS (www.carbogen-amcis.com) is a leading service provider offering a portfolio of drug development and commercialization services to the pharmaceutical and biopharmaceutical industries across all stages of clinical development and product life cycle. Our integrated services and innovative chemistry solutions support timely and safe drug development, allowing customers to better optimize available resources. CARBOGEN AMCIS is a wholly owned subsidiary of Dishman Carbogen Amcis Ltd, Ahmedabad, India.

Pascal Villemagne
Pascal Villemagne

Read more …Pascal Villemagne appointed new CARBOGEN AMCIS Chief Executive Officer (CEO)

  • Hits: 9311

Dishman Carbogen Amcis Ltd announces successful results from the partnership with Boston University School of Medicine on Clinical Research Study that reveals positive response in vitamin D deficiency/insufficiency in patients with COVID-19

News

Dishman Carbogen Amcis Ltd announces successful results from the partnership with Boston University School of Medicine on Clinical Research Study that reveals positive response in vitamin D deficiency/insufficiency in patients with COVID-19

Ahmedabad, India (December 9th, 2021) — Dishman Carbogen Amcis Ltd, a global outsourcing partner for the pharmaceutical industry, welcomes the results of a new Clinical Research Study which shows that oral 25-Hydroxyvitamin D3 (Calcifediol) was able to correct vitamin D deficiency/insufficiency in patients with COVID-19 and that it resulted in improved immune function by increasing blood lymphocyte percentages. The research was supervised by Tehran University of Medical Sciences and Boston University School of Medicine and supported in part by a grant from Dishman Carbogen Amcis Ltd’s wholly owned subsidiary CARBOGEN AMCIS B.V.

Dishman Carbogen Amcis Ltd (DCAL) is a leading global manufacturer of vitamin D plus its analogs and related APIs with over 70 years of experience in the field. DCAL partnered with Dr. Michael Holick, MD, PhD, professor of medicine, physiology and biophysics and molecular medicine at Boston University School of Medicine and its team for the Clinical Research Study to be run by the Tehran University of Medical Sciences on treatment with 25-Hydroxyvitamin D3 (Calcifediol) of hospitalized patients with COVID-19.

The study showed that patients receiving the 25-hydroxy metabolite had, in comparison to those receiving a placebo, a demonstrably more favorable development of their immunological defense against COVID-19. Thus, dosing the metabolite significantly increased the blood levels as well as the comparative percentage of lymphocytes in blood, i.e. a reduced Blood Neutrophil-to-Lymphocyte Ratio.

“A person’s vitamin D status is defined as the person’s blood level of the vitamin’s 25-hydroxy metabolite (Calcifediol), i.e. the vitamin’s natural form in circulation which the body can quickly access and finally activate. Therefore, Dishman Carbogen Amcis Ltd has for years studied the effects of dosing either the vitamin and/or the metabolite. Said Dr. Scott Miller, Sr. Scientific Advisor at DCAL, “Our support of this study of Calcifediol in the context of COVID-19 was motivated by the fact that the blood level of the metabolite can be increased more rapidly and more distinctly, if supplemented directly.”

To support the Clinical Research Study CARBOGEN AMCIS B.V. (Netherlands) provided the Active Pharmaceutical Ingredient (Calcifediol) and the capsules and placebo were made at Dishman Carbogen Amcis Ltd’s plant in Bavla, India, specifically for this study.

“There are several studies that have reported that a good vitamin D status i.e. a healthy blood level of 25-hydroxyvitamin D, can not only dramatically reduce the risk of being infected by this deadly virus but also a higher vitamin D status reduced risk for serious symptoms and death caused by the virus.” Commented Dr. Michael Holick. “This controlled study similar to the one conducted in Spain recently [1] demonstrate that the rapid improvement in vitamin D status can improve positive outcomes for patients infected with COVID 19.”

“The COVID-19 pandemic hitting the world in early 2020 resulted in unprecedented global focus of R&D efforts and of solidarity in coping with the sudden and unexpected high need for intensive care beds, which didn’t hit all countries to the same degree.” Said Arpit Vyas, Global Managing Director of Dishman Carbogen Amcis Ltd: “It is important for us to play a role in this new challenge, not only for our corporate interests but to contribute to the possible future of the fight against COVID-19. Therefore, to follow up with this Clinical Research Study, Dishman Carbogen Amcis Ltd is currently conducting a second round of study in a larger scale in India.”

For more information about the study supported by Dishman Carbogen Amcis Ltd:
https://www.sciencedirect.com/science/article/pii/S1530891X21012593

[1] “Effect of Calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study”
https://www.sciencedirect.com/science/article/pii/S0960076020302764

****

Dishman Carbogen Amcis Ltd (www.imdcal.com) is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and manufacturing services. Dishman Carbogen Amcis group improves its customers’ businesses by providing a range of development and manufacturing solutions at locations in Europe and in India.

CARBOGEN AMCIS AG (www.carbogen-amcis.com) is a leading service provider, offering a portfolio of drug-development and commercialization services to the pharmaceutical and biopharmaceutical industry at all stages of drug development. The integrated services provide innovative chemistry solutions to support timely and safe drug development, allowing customers to make the best use of available resources. CARBOGEN AMCIS AG is owned by Dishman Carbogen Amcis Ltd., Ahmedabad, India.

OTHER NEWS

Company Profile

CONTACT US TODAY OR DOWNLOAD
OUR COMPANY PROFILE BROCHURE
FOR FURTHER INFORMATION

SUBSCRIBE TO OUR MAILING LIST FOR THE LATEST NEWS UPDATES

Read more …Dishman Carbogen Amcis Ltd announces successful results from the partnership with Boston...

  • Hits: 14248

Dishman Carbogen Amcis Ltd announces successful results from the partnership with Boston University School of Medicine on study that uncovers treatment for vitamin D deficiency

News

Dishman Carbogen Amcis Ltd announces successful results from the partnership with Boston University School of Medicine on study that uncovers treatment for vitamin D deficiency

Ahmedabad, India (May 21th, 2021) — India-based Dishman Carbogen Amcis Ltd, a global outsourcing partner for the pharmaceutical industry, welcomes the results of a new study that provides critical insights into the treatment of vitamin D deficiency in obesity and in fat malabsorption syndromes. The research was conducted by Boston University School of Medicine and supported in part by a grant from Dishman Carbogen Amcis Ltd’s wholly-owned subsidiary CARBOGEN AMCIS B.V.

Dishman Carbogen Amcis Ltd (DCAL) is a leading global manufacturer of vitamin D analogs and related APIs. DCAL partnered with Dr. Michael Holick, MD, Ph.D., professor of medicine, physiology, and biophysics and molecular medicine at Boston University School of Medicine, to determine whether alternative vitamin D-type substances provide significant health benefits in people suffering from impaired distribution and metabolism of vitamin D.

“We believe that partnerships with academic institutions help uncover important insights and make great discoveries that benefit the pharmaceutical industry and, most importantly, the patients directly”, said Arpit Vyas, Global Managing Director of Dishman Carbogen Amcis Ltd.

The study results will benefit obese people and, e.g., patients who have undergone gastric bypass surgery, which quite generally results in vitamin D malabsorption. Thus, those patients run an elevated risk of bone diseases like osteoporosis and osteomalacia due to softening of the bones.

Researchers observed that a form of vitamin D, known as 25-hydroxyvitamin D3 (Calcifediol), was absorbed faster and better than the same dose of vitamin D. “This vitamin D metabolite is better absorbed in patients with fat malabsorption syndromes and since it is not as fat-soluble, it does not get diluted in the body fat and is effective in raising and maintaining blood levels,” said Dr. Michael Holick. “Therefore, using 25-hydroxyvitamin D3 could be a novel approach for treating vitamin D deficiency in patients with fat malabsorption syndromes.”

CARBOGEN AMCIS B.V. provided the 25-hydroxyvitamin D3 capsules, which were produced at its parent company Dishman Carbogen Amcis Ltd’s Bavla facility in Ahmedabad, specifically for this study, thus becoming yet another global project for DCAL.

With over 70 years of vitamin D experience, DCAL is one of the leading innovators, developers, and manufacturers of vitamin D and its analogs. DCAL is engaged in these activities both at the DCAL location in Ahmedabad, India, and at its CARBOGEN AMCIS B.V. location in the Netherlands which is also active in the production and sales of vitamin D analogs (e.g., Alfacalcidol, Calcifediol, and Calcitriol), Ergocalciferol, and Cholesterol and lanolin related products for key markets as pharmaceutical, cosmetic, food, feed as well as industrial applications. DCAL manufactures raw material for vitamin D ingredients and develops a range of vitamin D analogs and metabolites which are used as APIs in pharmaceutical products across the world.

“Our Vitamin D activities are a source of particular pride. Since 2007 when the Netherlands facility was acquired by DCAL we have continually invested to ensure that we remain at the forefront of innovation. Our industry partners rely on the quality of the APIs we deliver. Through this collaboration with Boston University School of Medicine, we sought to advance our industry’s understanding of the full potential of vitamin D supplements for patients with various needs,” said  Rob Eijkman, site director CARBOGEN AMCIS B.V., Netherlands.

“The collaboration with Boston University and Dr. Holick has been an exercise in complete focus upon patients of need and efficient solutions to meet that need,” commented Dr. Peter Müller, senior scientific advisor for DCAL. “Dishman Carbogen Amcis Ltd has worked closely with Boston University School of Medicine on investigating the roles that vitamin D substances play in humans. In addition to the results of the study addressed here, the partnership has resulted in a mutually beneficial exchange of scientific views, including participation by Dr. Holick in scientific forums at DCAL.”

For more information about the Boston University study supported by Dishman Carbogen Amcis Ltd: https://academic.oup.com/ajcn/advance-article-abstract/doi/10.1093/ajcn/nqab123/6277980?redirectedFrom=fulltext

****

Dishman Carbogen Amcis Ltd (imdcal.com) is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up, and manufacturing services. Dishman Carbogen Amcis group improves its customers’ businesses by providing a range of development and manufacturing solutions at locations in Europe and in India.

CARBOGEN AMCIS AG (www.carbogenamcis.com) is a leading service provider offering a portfolio of drug development and commercialization services to the pharmaceutical and biopharmaceutical industries across all stages of clinical development and product life cycle. Our integrated services and innovative chemistry solutions support timely and safe drug development, allowing customers to better optimize available resources. CARBOGEN AMCIS is a wholly-owned subsidiary of Dishman Carbogen Amcis Ltd, Ahmedabad, India.

OTHER NEWS

Company Profile

CONTACT US TODAY OR DOWNLOAD
OUR COMPANY PROFILE BROCHURE
FOR FURTHER INFORMATION

SUBSCRIBE TO OUR MAILING LIST FOR THE LATEST NEWS UPDATES

Read more …Dishman Carbogen Amcis Ltd announces successful results from the partnership with Boston...

  • Hits: 12462

CARBOGEN AMCIS announces major investments of more than CHF 100 million in Switzerland and France

News

CARBOGEN AMCIS announces major investments of more than CHF 100 million in Switzerland and France

BUBENDORF, Switzerland (August 17, 2020) — Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, announced today new expansion plans in Switzerland and France. 

CARBOGEN AMCIS announces two major expansion projects that will increase manufacturing capacity to better meet the demands of the current market and its customers. The new facilities, located in Switzerland and France, will be phased in over the next four years, totaling investments in excess of CHF 100m (over €90 million). This follows six years of constant growth for the company.

In Switzerland, the project will be initiated in 2021 with construction of a new API manufacturing facility at its Hunzenschwil site. This project will progress in several phases. It is planned for this new unit to be operational by summer 2024.

“The facility is designed to provide space for CARBOGEN AMCIS to grow over the next 10 years with the initial phase comprising of 12 new vessels (from 630 liters to 4000 liters) and associated filtration and drying capabilities,” said Stephan Fritschi, vice president of operations. “We have an impressive pipeline, and now our customers can benefit from more diverse offerings.”

In addition to the new Swiss API manufacturing facility, additional investments are planned with a dedicated budget to improve some of the existing technologies and to increase the capacity of the current Swiss sites, such as adding chromatography equipment, new reactors in production and new laboratories.

In France, on newly acquired land located 7 km from an existing site in Riom, construction will begin in January 2021 with a new, state-of-the-art facility dedicated to custom development and manufacturing of parenteral drug products. This facility will allow handling complex formulations, including a large range of different types of APIs from biologics to any kind of highly potent compounds.

“After years of growth, it’s exciting to have reached our current production limits and to be able to expand our facilities and grow our capacity, which will match the future market demand,” said Pascal Villemagne, vice president of sales and marketing. “Our new facility in Riom will not only enable us to support more customers, but will also give them access to innovative fill and finish technologies.”

The new French site will be able to supply both clinical batches up to phase III and small-scale for commercial. There will be two automated lines: the first one for both liquid filling plus lyophilization and the second one dedicated to liquid forms. In addition, state-of-the-art development and analytical laboratories will be incorporated to support customer projects. Operations will commence during Q1 of 2023.

“Our objective is ambitious, nevertheless, we are taking a responsible approach to our growth in order to give the company and our employees a sustainable future. As an established leader in the pharmaceutical outsourcing industry for the past 40 years and with strong relationships with our customers, our company is ready to take this next step in capability and capacity. We are embarking on the expansions in order to secure CARBOGEN AMCIS’s position,” said Mark Griffiths, CARBOGEN AMCIS CEO.

Photo caption: The new facility in Riom, France will allow CARBOGEN AMCIS to support more customers and enables access to innovative fill and finish technologies.


CARBOGEN AMCIS (www.carbogen-amcis.com) is a leading service provider, offering a portfolio of drug-development and commercialization services to the pharmaceutical and biopharmaceutical industry at all stages of drug development. The integrated services provide innovative chemistry solutions to support timely and safe drug development, allowing customers to make the best use of available resources. CARBOGEN AMCIS is owned by Dishman Carbogen Amcis Ltd, Ahmedabad, India. 

Dishman Carbogen Amcis Ltd (www.dishmangroup.com) is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and manufacturing services. Dishman Carbogen Amcis group improves its customers’ businesses by providing a range of development and manufacturing solutions at locations in India. 

OTHER NEWS

Company Profile

CONTACT US TODAY OR DOWNLOAD
OUR COMPANY PROFILE BROCHURE
FOR FURTHER INFORMATION

SUBSCRIBE TO OUR MAILING LIST FOR THE LATEST NEWS UPDATES

Read more …CARBOGEN AMCIS announces major investments of more than CHF 100 million in Switzerland and France

  • Hits: 20993